A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease
Latest Information Update: 26 Jun 2025
At a glance
- Drugs Troculeucel (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors NKGen Biotech
Most Recent Events
- 23 Jun 2025 According to a NKGen Biotech media release, the company has received clearance from Health Canada for its Clinical Trial Application (CTA).
- 23 Jun 2025 According to a NKGen Biotech media release, the company announced the activation of two additional clinical trial sites. The newly activated sites, Ottawa Memory Clinic in Canada and AdventHealth Orlando in Florida, USA, are now open for patient enrollment, broadening access and accelerating recruitment for the trial.
- 07 May 2025 According to a NKGen Biotech media release, data from the phase 1 part of this phase 1/2a trial will be presented at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which will take place in New Orleans, Louisiana from May 13-17, 2025.